Seeking Alpha

Pluristem muscle treatment meets endpoints in trial

  • Pluristem's (PSTI +5%) PLX-PAD placenta-derived stem-cell therapy for muscle injuries appeared to be safe and effective in treating orthopedic injuries in a Phase I/II trial
  • "Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group," Pluristem says. The injured muscle studied was the gluteus medius in the buttock.
  • The trial participants who received the treatment showed a 300% improvement vs a placebo.
Comments (2)
  • Gotta love it: PSTI has great research results, down 5%.


    IMUC has no news, up 50 percent in two trading days.


    ATHX has no news, up 150 percent the last two months.
    21 Jan, 09:31 PM Reply Like
  • Any thoughts as to why this is?
    24 Jan, 04:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)